gilead.com

Analisi sito web gilead.com

 Generato il Dicembre 14 2022 00:39 AM

Statistiche non aggiornate? AGGIORNA !

Il punteggio e 56/100





SEO Content

Title

Gilead Sciences, Inc.

Lunghezza : 21

Idealmente, il tuo title dovrebbe contenere tra 40 e 70 caratteri (spazi inclusi). Usa questo strumento free per calcolare la lunghezza del testo.

Description

Gilead Sciences, Inc. is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines.

Lunghezza : 153

Grande, la tua meta description contiene tra 90 e 160 caratteri.

Keywords

Molto male. Non abbiamo trovato meta keywords nella tua pagina. Usa questo generatore gratuito online di meta tags per creare keywords.

Og Meta Properties

Buono, questa pagina sfrutta i vantaggi Og Properties.

Proprieta Contenuto
title Gilead Sciences, Inc.
description Gilead Sciences, Inc. is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines.
image https://wwwam10.gilead.com/-/media/gilead-corporate/images/og/gilead_logo.jpg

Headings

H1 H2 H3 H4 H5 H6
1 7 4 3 1 0
  • [H1] World AIDS Day: Striving Together Toward Equity
  • [H2] Contact
  • [H2] Creating a Better Healthier World
  • [H2] Connecting Breast Cancer Education to Community: Equal Hope
  • [H2] Latinas Contra Cancer Empowers Patients to Advocate for Change
  • [H2] Tatiana Williams Leads the Way with the Transinclusive Group
  • [H2] Social
  • [H2] Headline
  • [H3] Advancing Global Health
  • [H3] Sustainability
  • [H3] Partnerships and Community
  • [H3] Recent Stories
  • [H4] Community
  • [H4] Community
  • [H4] Community
  • [H5] Recent News

Images

Abbiamo trovato 16 immagini in questa pagina web.

Buono, molte o tutte le tue immagini hanno attributo alt

Text/HTML Ratio

Ratio : 40%

Ideale! Il rapporto testo/codice HTML di questa pagina e tra 25 e 70 percento.

Flash

Perfetto, non e stato rilevato contenuto Flash in questa pagina.

Iframe

Molto male, hai usato Iframes nelle tue pagine web, questo significa che in contenuto inserito negli Iframe non puo essere indicizzato.

URL Rewrite

Buono. I tuoi links appaiono friendly!

Underscores in the URLs

Perfetto! Non sono stati rilevati underscores nei tuoi URLs.

In-page links

Abbiamo trovato un totale di 161 links inclusi 1 link(s) a files

Anchor Type Juice
Medicine Questions Externo Passing Juice
Report an Adverse Event Interno Passing Juice
Investors Interno Passing Juice
Contact Interno Passing Juice
Canada Externo Passing Juice
Mexico Interno Passing Juice
USA Interno Passing Juice
Argentina Interno Passing Juice
Brazil Interno Passing Juice
China Mainland Externo Passing Juice
Hong Kong Interno Passing Juice
India Interno Passing Juice
Japan Externo Passing Juice
Korea Externo Passing Juice
Singapore Interno Passing Juice
Taiwan Interno Passing Juice
Israel Externo Passing Juice
Saudi Arabia Interno Passing Juice
Türkiye Interno Passing Juice
United Arab Emirates Interno Passing Juice
South Africa Interno Passing Juice
Australia and New Zealand Interno Passing Juice
Austria Interno Passing Juice
Belgium and Luxembourg Externo Passing Juice
Czech Republic & Slovakia Interno Passing Juice
Denmark Interno Passing Juice
Finland Interno Passing Juice
France Externo Passing Juice
Germany Externo Passing Juice
Greece Interno Passing Juice
Iceland Interno Passing Juice
Ireland Interno Passing Juice
Italy Externo Passing Juice
Netherlands Interno Passing Juice
Norway Interno Passing Juice
Poland & The Baltics Interno Passing Juice
Portugal Interno Passing Juice
Romania Interno Passing Juice
Russia Interno Passing Juice
Spain Externo Passing Juice
Sweden Interno Passing Juice
Switzerland Interno Passing Juice
United Kingdom Externo Passing Juice
Mission and Core Values Interno Passing Juice
Partnerships and Community Interno Passing Juice
Inclusion and Diversity Interno Passing Juice
Corporate Giving Interno Passing Juice
Gilead Foundation Interno Passing Juice
Sustainability Interno Passing Juice
Advancing Global Health Interno Passing Juice
Medication Access Interno Passing Juice
Leadership Interno Passing Juice
How We Operate Interno Passing Juice
Ethics and Code of Conduct Interno Passing Juice
Therapeutic Areas Interno Passing Juice
Medicines Interno Passing Juice
Pipeline Interno Passing Juice
Research Interno Passing Juice
Clinical Trials Externo Passing Juice
Events Interno Passing Juice
Stories Interno Passing Juice
Newsroom Interno Passing Juice
Company Statements Interno Passing Juice
Annual Reports Interno Passing Juice
Careers at Gilead Interno Passing Juice
Our Culture Interno Passing Juice
Meet Our Employees Interno Passing Juice
Inclusion and Diversity in Hiring Interno Passing Juice
Compensation, Benefits and Wellbeing Interno Passing Juice
Our Global Footprint Interno Passing Juice
Early Career Opportunities Interno Passing Juice
Postdoctoral Fellowships Interno Passing Juice
Hiring Events Externo Passing Juice
Talent Community Sign-up Externo Passing Juice
Privacy Statements Interno Passing Juice
Terms Of Use Interno Passing Juice
Social Media Guidelines Interno Passing Juice
EU Data Disclosure Interno Passing Juice
Sitemap Interno Passing Juice
BACK TO MAIN MENU Interno Passing Juice
COMPASS Initiative Interno Passing Juice
HepConnect Interno Passing Juice
HIV Age Positively Interno Passing Juice
Lift Interno Passing Juice
RADIAN Interno Passing Juice
TRANScend Interno Passing Juice
What We Fund Interno Passing Juice
Funding Requests Interno Passing Juice
Zeroing In: Ending the HIV Epidemic Interno Passing Juice
Creating Possible Fund Interno Passing Juice
Our Business Is Sustainable Interno Passing Juice
Performance Interno Passing Juice
Reporting Interno Passing Juice
U.N. Global Compact Interno Passing Juice
U.N. Sustainable Development Goals Interno Passing Juice
COVID-19 Interno Passing Juice
HCV Elimination Interno Passing Juice
U.S. Patient Access Interno Passing Juice
Disaster Product Replacement Interno Passing Juice
Global Access Interno Passing Juice
Authorized Distributors Interno Passing Juice
ESG Goals Interno Passing Juice
Governance Interno Passing Juice
Transparency Interno Passing Juice
Policies Interno Passing Juice
Anti-Bribery and Anti-Corruption Policy Interno Passing Juice
Animal Use and Welfare Policy Interno Passing Juice
Disclosures Interno Passing Juice
Anti-Counterfeiting Interno Passing Juice
Consumer Product Safety Interno Passing Juice
Supplier Information Interno Passing Juice
Political Engagement Interno Passing Juice
Research Scholars Program Interno Passing Juice
Compassionate Use Interno Passing Juice
Investigator-Sponsored Research Interno Passing Juice
Press Releases Interno Passing Juice
Media Inquiries Interno Passing Juice
Gilead Receives Complete Response Letter from U.S. FDA for Bulevirtide for the Treatment of Adults with Hepatitis Delta Virus Interno Passing Juice
Gilead Continues Efforts to Halt the Distribution of Counterfeit HIV Medications and Protect Patient Safety Interno Passing Juice
Veklury® (Remdesivir) Demonstrates Continued In Vitro Antiviral Activity Against Omicron Subvariants, Including BA.4 and BA.5 Interno Passing Juice
Sacituzumab Govitecan-Hziy Trodelvy Elevated to Category 1 Preferred Recommendation in Second-Line Metastatic Triple-Negative Breast Cancer Interno Passing Juice
Gilead Sciences Statement on FDA Acceptance of New Drug Application for Investigational Lenacapavir Interno Passing Juice
Gilead Statement on U.S. Supreme Court Overturning Roe v. Wade Interno Passing Juice
All Magrolimab Studies Re-Opening for Patient Enrollment in the U.S. Interno Passing Juice
Gilead Statement on WHO Recommendation of Veklury® (Remdesivir) and Acceleration of Prequalification Submission Interno Passing Juice
Gilead Implements Contract Pharmacy Integrity Initiative for Branded Hepatitis C Products Interno Passing Juice
Gilead to Expand Footprint in Oceanside Interno Passing Juice
Gilead Expands Availability of Veklury® (remdesivir) to Non-Hospital Outpatient Facilities Interno Passing Juice
Gilead Announces Global Resolution of Bictegravir Patent Dispute with ViiV Healthcare Interno Passing Juice
Gilead Announces Actions to Remove Counterfeit HIV Medications from US Supply Chain Interno Passing Juice
Gilead Statement on Zydelig® U.S. Indication for Follicular Lymphoma and Small Lymphocytic Leukemia Interno Passing Juice
Veklury® (Remdesivir) Receives Positive CHMP Opinion for the Treatment of Adults Not on Supplemental Oxygen and Considered High Risk for COVID-19 Disease Progression Interno Passing Juice
Gilead Issues a Voluntary Nationwide Recall of Two Lots of Veklury® (Remdesivir) Due to Presence of Glass Particulates Interno Passing Juice
Gilead Statement on Veklury® (Remdesivir) and the SARS-CoV-2 Omicron Variant Interno Passing Juice
Gilead and Merck Announce Temporary Pause in Enrollment for Phase 2 Study Evaluating an Oral Weekly Combination Regimen of Investigational Islatravir and Investigational Lenacapavir Interno Passing Juice
Gilead Announces Decision Not to Pursue Marketing Authorization for Descovy® for Pre-Exposure Prophylaxis in the European Union Interno Passing Juice
Gilead Statement on New NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Recommendation for Sacituzumab Govitecan-Hziy (Trodelvy®) in Second-Line and Later Metastatic Triple-Negative Breast Cancer Interno Passing Juice
Gilead Sciences Statement on Requiring Vaccination Against COVID-19 for Employees Interno Passing Juice
Gilead Warns of Counterfeit HIV Medication Being Distributed in the United States Interno Passing Juice
Gilead Sciences Statement on Positive Phase 3 AMBITION Study Findings for the Treatment of HIV-Associated Cryptococcal Meningitis Interno Passing Juice
Gilead Sciences Response to Open Letter Regarding Access to AmBisome® (liposomal amphotericin B) Interno Passing Juice
Gilead Statement on New England Journal of Medicine Publication of Positive Phase 3 ASCENT Study of Trodelvy in Metastatic Triple-Negative Breast Cancer Interno Passing Juice
Gilead Sciences Statement on Phase 3 Veklury® (Remdesivir) Intravenous Study in High Risk Non-Hospitalized Patients with COVID-19 Interno Passing Juice
Gilead Announces Additional Updates to The Advancing ACCESS® Patient Assistance/Medication Assistance Program Interno Passing Juice
Gilead Announces Updates to The Advancing ACCESS® Patient Assistance/Medication Assistance Program Interno Passing Juice
Gilead Announces Plans for New Location in North Carolina’s Research Triangle Region Dedicated to Business Services Interno Passing Juice
Gilead Sciences Statement on the Passing of the Honorable George P. Shultz, PhD Interno Passing Juice
Gilead Sciences Statement on Recent Events in Washington, D.C. Interno Passing Juice
Gilead Announces New Arm of HIV Women’s Prevention Study to Evaluate the Investigational Long-Acting HIV-1 Capsid Inhibitor Lenacapavir in Addition to Descovy for PrEP® Interno Passing Juice
Gilead Sciences Statement on The World Health Organization’s Updated Veklury® (Remdesivir) COVID-19 Treatment Guidelines Interno Passing Juice
- Interno Passing Juice
- Interno Passing Juice
Year in Review 2021 Interno Passing Juice
Cookie Statement Interno Passing Juice
Partnership Request Interno Passing Juice
Gilead Sciences Again Named to Dow Jones Sustainability World Index Interno Passing Juice
New Analyses of Kite's Tecartus® CAR T-Cell Therapy Provide Additional Evidence Supporting Overall Survival and Durability of Response Interno Passing Juice
- Externo Passing Juice
Stories@Gilead Interno Passing Juice
Investor Calls Interno Passing Juice
Modern Slavery Act Statement Interno Passing Juice

SEO Keywords

Keywords Cloud

main      community      menu      together      hiv      sciences      back      remdesivir      gilead      statement     

Consistenza Keywords

Keyword Contenuto Title Keywords Description Headings
gilead 37
back 16
main 16
menu 16
statement 16

Usabilita

Url

Dominio : gilead.com

Lunghezza : 10

Favicon

Grande, il tuo sito usa una favicon.

Stampabilita

Non abbiamo riscontrato codice CSS Print-Friendly.

Lingua

Buono. La tua lingua dichiarata en.

Dublin Core

Questa pagina non sfrutta i vantaggi di Dublin Core.

Documento

Doctype

HTML 5

Encoding

Perfetto. Hai dichiarato che il tuo charset e UTF-8.

Validita W3C

Errori : 12

Avvisi : 15

Email Privacy

Attenzione! E stato trovato almeno un indirizzo mail in plain text. Usa antispam protector gratuito per nascondere gli indirizzi mail agli spammers.

Deprecated HTML

Grande! Non abbiamo trovato tags HTML deprecati nel tuo codice.

Suggerimenti per velocizzare

Eccellente, il tuo sito web non utilizza nested tables.
Molto male, il tuo sito web utilizza stili CSS inline.
Grande, il tuo sito web ha pochi file CSS.
Molto male, il tuo sito web ha troppi file JS (piu di 6).
Perfetto, il vostro sito si avvale di gzip.

Mobile

Mobile Optimization

Apple Icon
Meta Viewport Tag
Flash content

Ottimizzazione

XML Sitemap

Non trovato

Il tuo sito web non ha una sitemap XML - questo può essere problematico.

A elenca sitemap URL che sono disponibili per la scansione e possono includere informazioni aggiuntive come gli ultimi aggiornamenti del tuo sito, frequenza delle variazioni e l'importanza degli URL. In questo modo i motori di ricerca di eseguire la scansione del sito in modo più intelligente.

Robots.txt

http://gilead.com/robots.txt

Grande, il vostro sito ha un file robots.txt.

Analytics

Non trovato

Non abbiamo rilevato uno strumento di analisi installato su questo sito web.

Web analytics consentono di misurare l'attività dei visitatori sul tuo sito web. Si dovrebbe avere installato almeno un strumento di analisi, ma può anche essere buona per installare una seconda, al fine di un controllo incrociato dei dati.

PageSpeed Insights

Dispositivo
Categorie

Website Review

Website Review e uno strumento di ottimizzazione per i motori di ricerca (seo tool) che serve per analizzare le tue pagine web